Promising pill targets root cause of rare cold-triggered anemia

NCT ID NCT06067048

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Apr 02, 2026 · Last updated May 23, 2026 · Updated 7 times

Summary

This study tests a daily pill called zanubrutinib for people with cold agglutinin disease, a rare condition where the immune system mistakenly destroys red blood cells, especially in cold weather. The drug aims to stop the abnormal immune cells from attacking red blood cells, potentially reducing anemia and cold-related symptoms. About 25 adults with this disease will receive the treatment for 6 cycles to see if it improves their blood counts and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AZ Delta

Roeselare, Belgium
Amsterdan UMC ( location AMC)

Amsterdam, Netherlands
Erasusmc

Rotterdam, Netherlands
Haukeland University Hospital Bergen

Bergen, Norway
Odense University Hospital

Odense, Denmark
Oslo University Hospital

Oslo, Norway
Rigshospitalet

Copenhagen, Denmark
UMCG

Groningen, Netherlands
UZ leuven

Leuven, Belgium
st. Olavs Hospital

Trondheim, Norway

Conditions

Explore the condition pages connected to this study.

LYMPHOMA